US-based MedImmune, the global biologics research and development arm of Anglo-Swedish drug major AstraZeneca (LSE: AZN), has named Yong-Jun Liu as the company’s new head of research, effective January 6, 2014. Dr Liu currently serves as vice president and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute for Immunology Research.
Dr Liu will be responsible for driving pre-clinical research in multiple therapeutic areas to help advance drug candidates from discovery to development. Previously he was the head of cancer immunology research at the MD Anderson Cancer Center where he built the nation’s leading immunology department as judged by top publications and grants.
Bahija Jallal, executive vice president of MedImmune, said: “I am delighted to welcome Dr. Liu to MedImmune as our new head of research. Scientific leadership is our top priority. We are committed to hiring established leaders who will drive our research engine and progress our efforts to deliver valuable medicines to patients.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze